{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:34:06Z","timestamp":1794580446700,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41366-026-02088-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:57:15Z","timestamp":1777114635000},"page":"1603-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-4702","authenticated-orcid":false,"given":"Nadia","family":"Sawicka-Gutaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4183","authenticated-orcid":false,"given":"Dawid","family":"Gruszczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-5985","authenticated-orcid":false,"given":"Kacper","family":"Nijakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-2679","authenticated-orcid":false,"given":"Aleksandra","family":"Derwich-Rudowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Krenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7220","authenticated-orcid":false,"given":"Marek","family":"Rucha\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2088_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102882","volume":"46","author":"ANMS Islam","year":"2024","unstructured":"Islam ANMS, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: A meta-analysis. Prev Med Rep. 2024;46:102882.","journal-title":"Prev Med Rep"},{"key":"2088_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diab Endocrinol. 2025;13:221\u201362.","journal-title":"Lancet Diab Endocrinol"},{"key":"2088_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7861\/clinmed.2023-0168","volume":"23","author":"B Masood","year":"2023","unstructured":"Masood B, Moorthy M. Causes of obesity: a review. Clin Med (Lond). 2023;23:284\u201391.","journal-title":"Clin Med (Lond)"},{"key":"2088_CR4","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier CP, Burke VCLE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease. Circulation. 2021;143:e984\u20131010.","journal-title":"Circulation"},{"key":"2088_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615375","volume":"10","author":"T Scully","year":"2021","unstructured":"Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, Type 2 Diabetes, and Cancer Risk. Front Oncol. 2021;10:615375.","journal-title":"Front Oncol"},{"key":"2088_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s13679-018-0319-6","volume":"7","author":"DB Sarwer","year":"2018","unstructured":"Sarwer DB, Hanson AJ, Voeller J, Steffen K. Obesity and Sexual Functioning. Curr Obes Rep. 2018;7:301\u20137.","journal-title":"Curr Obes Rep"},{"key":"2088_CR7","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults A Review. JAMA. 2023;330:2000\u201315.","journal-title":"JAMA"},{"key":"2088_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2088_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740\u201356.","journal-title":"Cell Metab"},{"key":"2088_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1590530","volume":"6","author":"BF Hammad","year":"2025","unstructured":"Hammad BF, Zafar N, Ullah M, Faisal SJ, Iftikhar F, Waheed H, et al. Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review. Front Clin Diab Health. 2025;6:1590530.","journal-title":"Front Clin Diab Health"},{"key":"2088_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234.","journal-title":"Signal Transduct Target Ther"},{"key":"2088_CR12","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.3390\/ijms25158214","volume":"25","author":"Z Szekeres","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review. Int J Mol Sci. 2024;25:8214.","journal-title":"Int J Mol Sci"},{"key":"2088_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4093\/dmj.2023.0011","volume":"47","author":"SM An","year":"2023","unstructured":"An SM, Cho SH, Yoon JC. Adipose Tissue and Metabolic Health. Diab Metab J. 2023;47:595\u2013611.","journal-title":"Diab Metab J"},{"key":"2088_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154044","volume":"103","author":"AA Gurjar","year":"2020","unstructured":"Gurjar AA, Kushwaha S, Chattopadhyay S, Das N, Pal S, China SP, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism. 2020;103:154044.","journal-title":"Metabolism"},{"key":"2088_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/1573399810666141017153749","volume":"10","author":"H Abdulla","year":"2014","unstructured":"Abdulla H, Phillips B, Smith K, Wilkinson D, Atherton PJ, Idris I. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Curr Diab Rev. 2014;10:327\u201335.","journal-title":"Curr Diab Rev"},{"key":"2088_CR16","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/DMSO.S425642","volume":"16","author":"J Xiang","year":"2023","unstructured":"Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diab Metab Syndr Obes. 2023;16:2433\u201346.","journal-title":"Diab Metab Syndr Obes"},{"key":"2088_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/dom.16012","volume":"27","author":"R Jiao","year":"2025","unstructured":"Jiao R, Lin C, Cai X, Wang J, Wang Y, Lv F, et al. Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis. Diab, Obes Metab. 2025;27:259\u201367.","journal-title":"Diab, Obes Metab"},{"key":"2088_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metab - Clin Exp. 2025;164:156113.","journal-title":"Metab - Clin Exp"},{"key":"2088_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1532-5415.1991.tb03592.x","volume":"39","author":"RL Reed","year":"1991","unstructured":"Reed RL, Pearlmutter L, Yochum K, Meredith KE, Mooradian AD. The relationship between muscle mass and muscle strength in the elderly. J Am Geriatr Soc. 1991;39:555\u201361.","journal-title":"J Am Geriatr Soc"},{"key":"2088_CR20","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393:2636\u201346.","journal-title":"Lancet"},{"key":"2088_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12178-025-09978-3","volume":"18","author":"A Gatto","year":"2025","unstructured":"Gatto A, Liu K, Milan N, Wong S. The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Curr Rev Musculoskelet Med. 2025;18:469\u201380.","journal-title":"Curr Rev Musculoskelet Med"},{"key":"2088_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100283","volume":"22","author":"H Zakaria","year":"2024","unstructured":"Zakaria H, Alshehhi S, Caccelli M, Ozkan C, Kattan J, Jafaar Z, et al. Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study. Metab Open. 2024;22:100283.","journal-title":"Metab Open"},{"key":"2088_CR23","doi-asserted-by":"publisher","first-page":"951570","DOI":"10.3389\/fendo.2022.951570","volume":"13","author":"D Yu","year":"2022","unstructured":"Yu D, Zou M, Pan Q, Song Y, Li M, Zhang X, et al. Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study. Front Endocrinol. 2022;13:951570.","journal-title":"Front Endocrinol"},{"key":"2088_CR24","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s13304-024-01828-0","volume":"76","author":"MPS Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz MPS, Bland\u00f3n JDR, Gutierrez ISC, Mendoza CMM, Agui\u00f1aga MSA, Orozco CAO. Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery. Updates Surg. 2024;76:2277\u201383.","journal-title":"Updates Surg"},{"key":"2088_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.diabet.2017.12.007","volume":"44","author":"E Capristo","year":"2018","unstructured":"Capristo E, Panunzi S, De Gaetano A, Raffaelli M, Guidone C, Iaconelli A, et al. Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study. Diab Metab. 2018;44:235\u201342.","journal-title":"Diab Metab"},{"key":"2088_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386542","volume":"15","author":"B Rodr\u00edguez Jim\u00e9nez","year":"2024","unstructured":"Rodr\u00edguez Jim\u00e9nez B, Rodr\u00edguez de Vera G\u00f3mez P, Belmonte Lomas S, Mesa D\u00edaz \u00c1M, Caballero Mateos I, Gal\u00e1n I, et al. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2024;15:1386542.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2088_CR27","first-page":"9908","volume":"27","author":"J Xiang","year":"2023","unstructured":"Xiang J, Ding XY, Zhang W, Zhang J, Zhang YS, Li ZM, et al. Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults. Eur Rev Med Pharm Sci. 2023;27:9908\u201315.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"2088_CR28","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.3390\/jcm13164752","volume":"13","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, Ronconi V, Sguanci M, Palomares SM, Mancin S, Tartaglia FC, et al. Oral Semaglutide in Type 2 Diabetes: Clinical\u2013Metabolic Outcomes and Quality of Life in Real-World Practice. J Clin Med. 2024;13:4752.","journal-title":"J Clin Med"},{"key":"2088_CR29","doi-asserted-by":"publisher","first-page":"1240263","DOI":"10.3389\/fendo.2023.1240263","volume":"14","author":"S Volpe","year":"2023","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, et al. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Front Endocrinol. 2023;14:1240263.","journal-title":"Front Endocrinol"},{"key":"2088_CR30","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","volume":"43","author":"O Anyiam","year":"2024","unstructured":"Anyiam O, Phillips B, Quinn K, Wilkinson D, Smith K, Atherton P, et al. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus. Clin Nutr. 2024;43:1907\u201313.","journal-title":"Clin Nutr"},{"key":"2088_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2147\/DMSO.S443631","volume":"17","author":"S Chen","year":"2024","unstructured":"Chen S, Wang X, Jin Y, Chen X, Song Q, Wei G, et al. Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment. Diab Metab Syndr Obes. 2024;17:1301\u20138.","journal-title":"Diab Metab Syndr Obes"},{"key":"2088_CR32","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/hepr.12837","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47:1206\u201311.","journal-title":"Hepatol Res"},{"key":"2088_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/nu15030556","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qu Z, Lu T, Shao X, Cai M, Dilimulati D, et al. Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2023;15:556.","journal-title":"Nutrients"},{"key":"2088_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.29271\/jcpsp.2023.03.308","volume":"33","author":"E Agcakaya","year":"2023","unstructured":"Agcakaya E, Mutlu HH, Erbakan A, Sargin M. Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition. J Coll Physicians Surg Pak. 2023;33:308\u201313.","journal-title":"J Coll Physicians Surg Pak"},{"key":"2088_CR35","doi-asserted-by":"publisher","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","volume":"7","author":"DJ Cuthbertson","year":"2012","unstructured":"Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, et al. Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. PLOS ONE. 2012;7:e50117.","journal-title":"PLOS ONE"},{"key":"2088_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.131","volume":"3","author":"V Mittag-Roussou","year":"2020","unstructured":"Mittag-Roussou V, Wagenpfeil S, Lammert F, Stokes CS. Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol Diab Metab. 2020;3:e00131.","journal-title":"Endocrinol Diab Metab"},{"key":"2088_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13841","volume":"26","author":"JI Mechanick","year":"2025","unstructured":"Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26:e13841.","journal-title":"Obes Rev"},{"key":"2088_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156057","volume":"161","author":"K Stefanakis","year":"2024","unstructured":"Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024;161:156057.","journal-title":"Metabolism"},{"key":"2088_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025;86:103363.","journal-title":"eClinicalMedicine"},{"key":"2088_CR40","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","volume":"28","author":"S Perna","year":"2016","unstructured":"Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28:1251\u20137.","journal-title":"Aging Clin Exp Res"},{"key":"2088_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/medicines9090047","volume":"9","author":"Y Ozeki","year":"2022","unstructured":"Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M, et al. The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study. Medicines. 2022;9:47.","journal-title":"Medicines"},{"key":"2088_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2022.100456","volume":"35","author":"K Vosoughi","year":"2022","unstructured":"Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. Obes Med. 2022;35:100456.","journal-title":"Obes Med"},{"key":"2088_CR43","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.3390\/ijms22157797","volume":"22","author":"Janssen JAMJL","year":"2021","unstructured":"Janssen JAMJL. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int J Mol Sci. 2021;22:7797.","journal-title":"Int J Mol Sci"},{"key":"2088_CR44","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.3390\/ijms25105488","volume":"25","author":"Janssen JAMJL","year":"2024","unstructured":"Janssen JAMJL. Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes. Int J Mol Sci. 2024;25:5488.","journal-title":"Int J Mol Sci"},{"key":"2088_CR45","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/ph18071058","volume":"18","author":"B Hong","year":"2025","unstructured":"Hong B, Kim H, Lee D, Kim K. Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2025;18:1058.","journal-title":"Pharmaceuticals"},{"key":"2088_CR46","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","volume":"39","author":"M Jensterle","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M, Jane\u017e A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther. 2022;39:2452\u201367.","journal-title":"Adv Ther"},{"key":"2088_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107866","volume":"219","author":"M Marassi","year":"2025","unstructured":"Marassi M, Cignarella A, Russo GT, Nollino L, Strazzabosco M, Marzullo P, et al. Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study. Pharmacol Res. 2025;219:107866.","journal-title":"Pharmacol Res"},{"key":"2088_CR48","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae165","volume":"166","author":"S B\u00f6rchers","year":"2025","unstructured":"B\u00f6rchers S, Skibicka KP. GLP-1 and Its Analogs: Does Sex Matter?. Endocrinology. 2025;166:bqae165.","journal-title":"Endocrinology"},{"key":"2088_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/jpm12030454","volume":"12","author":"E Rentzeperi","year":"2022","unstructured":"Rentzeperi E, Pegiou S, Koufakis T, Grammatiki M, Kotsa K. Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. J Pers Med. 2022;12:454.","journal-title":"J Pers Med"},{"key":"2088_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40618-023-02196-z","volume":"47","author":"G Muscogiuri","year":"2024","unstructured":"Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A. Obesity: a gender-view. J Endocrinol Invest. 2024;47:299\u2013306.","journal-title":"J Endocrinol Invest"},{"key":"2088_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molmet.2018.05.017","volume":"15","author":"M Gannon","year":"2018","unstructured":"Gannon M, Kulkarni RN, Tse HM, Mauvais-Jarvis F. Sex differences underlying pancreatic islet biology and its dysfunction. Mol Metab. 2018;15:82.","journal-title":"Mol Metab"},{"key":"2088_CR52","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, et al. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Prefer Adherence. 2020;14:2337\u201345.","journal-title":"Patient Prefer Adherence"},{"key":"2088_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40366-4","volume":"13","author":"FPC Freitas","year":"2023","unstructured":"Freitas FPC, Rodrigues CEM. Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome. Sci Rep. 2023;13:13090.","journal-title":"Sci Rep"},{"key":"2088_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/a-1608-0345","volume":"130","author":"L Gao","year":"2022","unstructured":"Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, et al. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. Exp Clin Endocrinol Diab. 2022;130:358\u201367.","journal-title":"Exp Clin Endocrinol Diab"},{"key":"2088_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/07435800.2014.966385","volume":"40","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015;40:133\u20138.","journal-title":"Endocr Res"},{"key":"2088_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015;14:81\u201390.","journal-title":"Hormones (Athens)"},{"key":"2088_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8:32.","journal-title":"J Ovarian Res"},{"key":"2088_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1475-2840-13-36","volume":"13","author":"CJ Li","year":"2014","unstructured":"Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.","journal-title":"Cardiovasc Diabetol"},{"key":"2088_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4274\/BMJ.galenos.2023.2023.6-5","volume":"19","author":"\u00d6 Akyay","year":"2023","unstructured":"Akyay \u00d6, Selek A, Tarkun \u0130, \u015eahi\u0307n T, Cant\u00fcrk Z, Arslan B, et al. Evaluation of Exenatide Versus Insulin Glargine Treatment\u2019s Impact on Brown Adipose Tissue Markers and Epicardial Adipose Tissue. Med J Bakirkoy. 2023;19:276\u201382.","journal-title":"Med J Bakirkoy"},{"key":"2088_CR60","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","volume":"106","author":"KE Elkind-Hirsch","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, Dapagliflozin, or Phentermine\/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021;106:3019\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"2088_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","volume":"10","author":"WH Feng","year":"2019","unstructured":"Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diab Investig. 2019;10:399\u2013407.","journal-title":"J Diab Investig"},{"key":"2088_CR62","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/nu14214673","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, et al. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients. 2022;14:4673.","journal-title":"Nutrients"},{"key":"2088_CR63","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/jdi.13270","volume":"11","author":"H Nakaguchi","year":"2020","unstructured":"Nakaguchi H, Kondo Y, Kyohara M, Konishi H, Oiwa K, Terauchi Y. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study. J Diab Investig. 2020;11:1542\u201350.","journal-title":"J Diab Investig"},{"key":"2088_CR64","first-page":"407","volume":"10","author":"M Rondanelli","year":"2016","unstructured":"Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10:407\u201313.","journal-title":"Patient Prefer Adherence"},{"key":"2088_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.14740\/jocmr4987","volume":"15","author":"S Uchiyama","year":"2023","unstructured":"Uchiyama S, Sada Y, Mihara S, Sasaki Y, Sone M, Tanaka Y. Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes. J Clin Med Res. 2023;15:377\u201383.","journal-title":"J Clin Med Res"},{"key":"2088_CR66","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/nu14122414","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Racaniello D, Fanelli M, Colaianni V, Vozza A, et al. Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. Nutrients. 2022;14:2414.","journal-title":"Nutrients"},{"key":"2088_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473\u201385.","journal-title":"Diabetologia"},{"key":"2088_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1394506","volume":"15","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G, et al. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front Endocrinol (Lausanne). 2024;15:1394506.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2088_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22:41.","journal-title":"Cardiovasc Diabetol"},{"key":"2088_CR70","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/jcm9103213","volume":"9","author":"L Vedtofte","year":"2020","unstructured":"Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, et al. One Year\u2019s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J Clin Med. 2020;9:3213.","journal-title":"J Clin Med"},{"key":"2088_CR71","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/dom.14882","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diab, Obes Metab. 2023;25:398\u2013406.","journal-title":"Diab, Obes Metab"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02088-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:02:49Z","timestamp":1786471369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02088-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2088"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02088-1","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}